Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation.
A survey of the previous literature and the data shown here indicate that neuroendocrine hormones such as growth hormone and prolactin may be of potential clinical use after bone marrow transplantation (BMT) to promote hematopoietic and immune recovery. The amounts of hormones used in our model do not promote weight gain suggesting that their lymphohematopoietic actions were independent of their anabolic effects. While the hormones may not produce the same extent of immune/hematopoietic effects when compared to conventional hematopoietic and immune stimulating cytokines (i.e. IL-2 or G-CSF), their pleiotropic effects and limited toxicity after systemic administration makes them attractive to test in the post-BMT setting. However, more work needs to be performed to understand the mechanism(s) of their action, particularly with regard to T-cell function and development.
Woody
M A
MA
Laboratory of Leukocyte Biology, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Md. 21702-1201, USA.
Welniak
L A
LA
Richards
S
S
Taub
D D
DD
Tian
Z
Z
Sun
R
R
Longo
D L
DL
Murphy
W J
WJ
D000818:Animals; D016026:Bone Marrow Transplantation; D013006:Growth Hormone / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000502:physiology; D011388:Prolactin / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000502:physiology
D011388:Prolactin; D013006:Growth Hormone